Macrogenics Inc is focused on exploiting the mechanisms by which cytotoxic antibodies mediate cell killing both for the development and improvement of existing therapeutic antibodies for the treatment of cancers and the development of therapeutics to prevent cytotoxic autoantibodies from triggering disease in autoimmunity. The firm is focused on product development derived from in-house and from in-licensed candidates in the areas of oncology, autoimmunity, antibody engineering and infectious disease. This multi-faceted approach in developing both antibodies and vaccines provides a diversified strategy for creating novel immunotherapeutics in areas of unmet medical need.
